Smart lipid nanoparticles containing levofloxacin and DNase for lung delivery. Design and characterization

Colloids and Surfaces B: Biointerfaces

Volumn 143, Issue , 2016, Pages 168-176

  Islan, Germán A ^a   Tornello, Pablo Cortez ^a,b   Abraham, Gustavo A ^b   Duran, Nelson ^c,d   Castro, Guillermo ^a  

^a Universidad Nacional de La Plata   (Argentina)

^b UNIVERSIDAD NACIONAL DE MAR DEL PLATA   (Argentina)

^c UNIVERSITY OF CAMPINAS   (Brazil)

^d BRAZILIAN CENTER FOR RESEARCH IN ENERGY AND MATERIALS CNPEM   (Brazil)

Author keywords

Cystic fibrosis; DNase; Levofloxacin; Nanostructured lipid carriers; Pulmonary delivery; Solid lipid nanoparticles

Indexed keywords

ADSORPTION ISOTHERMS; ANTIBIOTICS; BACTERIA; DRUG PRODUCTS; ENCAPSULATION; GAS ADSORPTION; LIGHT SCATTERING; LIGHT TRANSMISSION; SCANNING ELECTRON MICROSCOPY;

CYSTIC FIBROSIS; DNASE; LEVOFLOXACIN; NANOSTRUCTURED LIPID CARRIERS; PULMONARY DELIVERY; SOLID LIPID NANOPARTICLE (SLN);

NANOPARTICLES;

DEOXYRIBONUCLEASE; DEOXYRIBONUCLEASE I; LEVOFLOXACIN; MYRISTIC ACID; MYRISTYL MYRISTATE; NANOCARRIER; NANOSTRUCTURED LIPID CARRIER; POLOXAMER; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; DRUG CARRIER; LIPID; NANOPARTICLE;

ADSORPTION; ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CYSTIC FIBROSIS; DIFFUSION; DISPERSION; DRUG DELIVERY SYSTEM; DRUG RELEASE; ENCAPSULATION; HYDRODYNAMICS; IN VITRO STUDY; INFRARED SPECTROSCOPY; MICROSCOPY; NONHUMAN; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; PHYSICAL CHEMISTRY; POLYDISPERSION INDEX; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SCANNING ELECTRON MICROSCOPY; STAPHYLOCOCCUS AUREUS; STORAGE; THERMOGRAVIMETRY; TRANSMISSION ELECTRON MICROSCOPY; VISCOELASTICITY; X RAY DIFFRACTION; ZETA POTENTIAL; BIOFILM; CHEMISTRY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG EFFECTS; DRUG FORMULATION; GROWTH, DEVELOPMENT AND AGING; HUMAN; METABOLISM; MICROBIOLOGY; PHYSIOLOGY; PROCEDURES; ULTRASTRUCTURE;

ANTI-BACTERIAL AGENTS; BIOFILMS; CALORIMETRY, DIFFERENTIAL SCANNING; CYSTIC FIBROSIS; DEOXYRIBONUCLEASES; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG LIBERATION; HUMANS; LEVOFLOXACIN; LIPIDS; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PARTICLE SIZE; PSEUDOMONAS AERUGINOSA; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; X-RAY DIFFRACTION;

EID: 84961163390     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2016.03.040     Document Type: Article

References (44)

1. Cutting G.R. Cystic fibrosis genetics: from molecular understanding to clinical application. Nat. Rev. Genet. 2015, 16(1):45-56.
2. Stoltz D.A., Meyerholz D.K., Welsh M.J. Origins of cystic fibrosis lung disease. New Engl. J. Med. 2015, 372(4):351-362.
3. Folkesson A., Jelsbak L., Yang L., Johansen H.K., Ciofu O., Høiby N., Molin S. Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective. Nat. Rev. Microbiol. 2012, 10(12):841-851.
4. Ciofu O., Mandsberg L.F., Wang H., Høiby N. Phenotypes selected during chronic lung infection in cystic fibrosis patients: implications for the treatment of Pseudomonas aeruginosa biofilm infections. FEMS Immunol. Med. Microbiol. 2012, 65(2):215-225.
5. Hodges N.A., Gordon C.A. Protection of Pseudomonas aeruginosa against ciprofloxacin and beta-lactams by homologous alginate. Antimicrob. Agents Chemother. 1991, 35(11):2450-2452.
6. Lethem M., James S.L., Marriott C., Burke J.F. The origin of DNA associated with mucus glycoproteins in cystic fibrosis sputum. Eur. Respir. J. 1990, 3(1):19-23.
7. Papayannopoulos V., Staab D., Zychlinsky A. Neutrophil elastase enhances sputum solubilization in cystic fibrosis patients receiving DNase therapy. PLoS One 2011, 6(12):e28526.
8. Ratjen F., Döring G., Nikolaizik W.H. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 2001, 358(9286):983-984.
9. Gibson R.L., Emerson J., Mayer-Hamblett N., Burns J.L., McNamara S., Accurso F.J., Ramsey B.W. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr. Pulmonol. 2007, 42(7):610-623.
10. Kesser K.C., Geller D.E. New aerosol delivery devices for cystic fibrosis. Respir. Care 2009, 54(6):754-768.
11. Rose L.M., Neale R. Development of the first inhaled antibiotic for the treatment of cystic fibrosis. Sci. Transl. Med. 2010, 2(63). 63mr4.
12. Pesaturo K.A., Horton E.R., Belliveau P. Inhaled aztreonam lysine for cystic fibrosis pulmonary disease-related outcomes. Ann. Pharmacother. 2012, 46(7-8):1076-1085.
13. Döring G., Flume P., Heijerman H., Elborn J.S., Consensus Study Group Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J. Cyst. Fibros. 2012, 11(6):461-479.
14. Jaspart S., Bertholet P., Piel G., Dogné J.M., Delattre L., Evrard B. Solid lipid microparticles as a sustained release system for pulmonary drug delivery. Eur. J. Pharm. Biopharm. 2007, 65(1):47-56.
15. Liu J., Gong T., Fu H., Wang C., Wang X., Chen Q., Zhang Z. Solid lipid nanoparticles for pulmonary delivery of insulin. Int. J. Pharm. 2008, 356(1):333-344.
16. Varshosaz J., Ghaffari S., Mirshojaei S.F., Jafarian A., Atyabi F., Kobarfard F., Azarmi S. Biodistribution of amikacin solid lipid nanoparticles after pulmonary delivery. BioMed Res. Int. 2013, 8. Article ID 136859. 10.1155/2013/136859.
17. Nafee N., Husari A., Maurer C.K., Lu C., de Rossi C., Steinbach A., Hartmann R.W., Lehr C.M., Schneider M. Antibiotic-free nanotherapeutics: ultra-small: mucus-penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors. J. Controlled Release 2014, 192:131-140.
18. Ridolfi D.M., Marcato P.D., Justo G.Z., Cordi L., Machado D., Durán N. Chitosan-solid lipid nanoparticles as carriers for topical delivery of tretinoin. Colloids Surf. B 2012, 93:36-40.
19. Fang C.L., Al-Suwayeh A.S., Fang J.Y. Nanostructured lipid carriers (NLCs) for drug delivery and targeting. Recent Pat. Nanotechnol. 2013, 7(1):41-55.
20. Geller D.E., Flume P.A., Griffith D.C., Morgan E., White D., Loutit J.S., Dudley M.N. Pharmacokinetics and safety of MP-376 (Levofloxacin inhalation solution) in cystic fibrosis subjects. Antimicrob. Agents Chemother. 2011, 55(6):2636-2640.
21. Döring G., Dalhoff A. Aerosolised LVfloxacin in cystic fibrosis. Expert Opin. Orphan Drugs 2013, 1(7):549-556.
22. Carbon C. Comparison of side effects of LVfloxacin versus other fluoroquinolones. Hemotherapy 2001, 47(3):9-14.
23. Baig M.S., Ahad A., Aslam M., Imam S.S., Aqil M., Ali A. Application of Box-Behnken design for preparation of levofloxacin-loaded stearic acid solid lipid nanoparticles for ocular delivery: optimization in vitro release, ocular tolerance, and antibacterial activity. Int. J. Biol. Macromol. 2016, 85:258-270.
24. Suk J.S., Lai S.K., Wang Y.Y., Ensign L.M., Zeitlin P.L., Boyle M.P., Hanes J. The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles. Biomaterials 2009, 30(13):2591-2597.
25. Liu Y., He Q., Wu M. Levofloxacin-induced crystal nephropathy. Nephrology (Carlton) 2015, 20:437-438.
26. Ratjen F., Paul K., Van Koningsbruggen S., Breitenstein S., Rietschel E., Nikolaizik W. DNA concentrations in BAL fluid of cystic fibrosis patients with early lung disease: influence of treatment with dornase alpha. Pediatr. Pulmonol. 2005, 39(1):1-4.
27. Alipour M., Suntres Z.E., Omri A. Importance of DNase and alginate lyase for enhancing free and liposome encapsulated aminoglycoside activity against Pseudomonas aeruginosa?. J. Antimicrob. Chemother. 2009, 64(2):317-325.
28. Venkateswarlu V., Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J. Controlled Release 2004, 95(3):627-638.
29. Freitas C., Müller R.H. Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur. J. Pharm. Biopharm. 1999, 47:125-132.
30. North D.S., Fish D.N., Redington J.J. Levofloxacin, a second-generation fluoroquinolone. Pharmacother: J. Hum. Pharmacol. Drug Ther. 1998, 18(5):915-935.
31. Shah M., Agrawal Y.K., Garala K., Ramkishan A. Solid lipid nanoparticles of a water soluble drug, ciprofloxacin hydrochloride. Indian J. Pharm. Sci. 2012, 74(5):434.
32. Yang Y., Corona A., Schubert B., Reeder R., Henson M.A. The effect of oil type on the aggregation stability of nanostructured lipid carriers. J. Colloid Interface Sci. 2014, 418:261-272.
33. Siddiqui A., Alayoubi A., El-Malah Y., Nazzal S. Modeling the effect of sonication parameters on size and dispersion temperature of solid lipid nanoparticles (SLNs) by response surface methodology (RSM). Pharm. Dev. Technol. 2014, 19(3):342-346.
34. Schärtl W. Light scattering from polymer solutions and nanoparticle dispersions. Springer Sci. Bus. Media 2007.
35. Bhardwaj V., Bhardwaj T., Sharma K., Gupta A., Chauhan S., Cameotra S.S., Sharma S., Gupta R., Sharma P. Drug-surfactant interaction: thermo-acoustic investigation of sodium dodecyl sulfate and antimicrobial drug (levofloxacin) for potential pharmaceutical application. RSC Adv. 2014, 4:24935-24943.
36. Guterres S.S., Alves M.P., Pohlmann A.R. Polymeric nanoparticles, nanospheres and nanocapsules, for cutaneous applications. Drug Target Insights 2007, 2:147.
37. Wolgang S. Sample Preparation in Light Scattering from Polymer Solution and Nanoparticle Dispersions 2007, 43-44. Springer Berlin Heidelberg GmbH & Co. K, Berlin.
38. Gunasekaran S., Rajalakshmi K., Kumaresan S. Vibrational analysis, electronic structure and nonlinear optical properties of LVfloxacin by density functional theory. Spectrochim. Acta Part A: Mol. Biomol Spectrosc. 2013, 112:351-363.
39. Honary S., Zahir F. Effect of zeta potential on the properties of nano-drug delivery systems-a review (Part 2). Trop. J. Pharm. Res. 2013, 12:265-273.
40. Singh K.K., Pople P.V. Development and evaluation of topical formulation containing solid lipid nanoparticles of vitamin A. AAPS Pharm. Sci. Tech. 2006, 7(4):E63-9.
41. Islan G.A., Bosio V.E., Castro G.R. Alginate lyase and ciprofloxacin co-immobilization on biopolymeric microspheres for cystic fibrosis treatment. Macromol. Biosci. 2013, 13:1238-1248.
42. Islan G.A., Martinez Y.N., Illanes A., Castro G.R. Development of novel alginate lyase cross-linked aggregates for the oral treatment of cystic fibrosis. RSC Adv. 2014, 4:11758-11765.
43. Suk J.S., Kim A.J., Trehan K., Schneider C.S., Cebotaru L., Woodward O.M., Boylan N.J., Boyle M.P., Lai S.K., Guggino W.B., Hanes J. Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier. J. Controlled Release 2014, 178:8-17.
44. Kalam M.A., Sultana Y., Ali A., Aqil M., Mishra A.K., Chuttani K. Preparation, characterization, and evaluation of gatifloxacin loaded solid lipid nanoparticles as colloidal ocular drug delivery system. J. Drug Target. 2010, 18:191-204.